Table 4.
Area of fluorescent lesion in treatment and control groups at different time point (pixel).
| Group | Day 5 | Day 10 | Day 15 | Day 20 | Day 25 | Day 30 |
|---|---|---|---|---|---|---|
| (1) HD PAMAM-Esa | 223104 ± 60101 | 146451 ± 54606 | 83812 ± 52424 | 59549 ± 49634 | 33301 ± 36204 | 29676 ± 36394 |
| (2) LD PAMAM-Esb | 179970 ± 64910 | 111880 ± 59332 | 91058 ± 73949 | 55692 ± 46240 | 46290 ± 39019 | 43015 ± 41680 |
| (3) Lipofectamine-ESa,b | 194664 ± 62033 | 163435 ± 56293 | 113506 ± 50036 | 117513 ± 62957 | 120533 ± 71327 | 131120 ± 71257 |
| (4) PAMAMa,b | 200465 ± 58021 | 154130 ± 60652 | 128977 ± 62570 | 138480 ± 85150 | 160714 ± 105618 | 161172 ± 92100 |
| (5) PBSa,b | 184576 ± 57799 | 159941 ± 78005 | 130626 ± 50700 | 126370 ± 58317 | 111729 ± 44760 | 123874 ± 62956 |
aStatistic significant difference between Group 1 and Group 3, Group 1 and Group 4, and Group 1 and Group 5 by Bonferroni test. bStatistic significant difference between Group 2 and Group 3, Group 2 and Group 4, and Group 2 and Group 5 by Bonferroni test. (Injecting one dose of various medicines into the endometrial lesion in each group mouse on day 10.)